UllCORE is designed to transform life-saving clinical decision making for sepsis patients

UllCORE旨在改变脓毒症患者的救生临床决策

Barcelona, Spain – 25 April 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the unveiling of its UllCORE diagnostic system, currently in development, with its first application in early sepsis detection..

西班牙巴塞罗那–2024年4月25日–deepull是一家开发无培养诊断解决方案的医疗诊断公司，用于快速识别败血症和其他急性感染的病原体，今天宣布推出其目前正在开发的UllCORE诊断系统，该系统首次应用于早期败血症检测。。

UllCORE is a benchtop diagnostic system designed to deliver 50 reportable results in one hour covering 95% of sepsis-causing pathogens and resistance genes. The real-time multiplex PCR system extracts total microbial DNA from 8 mL of whole blood, circumventing the lengthy blood culture process. The assay includes a wide range of bacterial targets, fungi, and genetic determinants of antibiotic resistance.

UllCORE是一个台式诊断系统，旨在一小时内提供50个可报告的结果，覆盖95%的败血症病原体和耐药基因。实时多重PCR系统从8毫升全血中提取总微生物DNA，避免了漫长的血液培养过程。该测定包括多种细菌靶标，真菌和抗生素耐药性的遗传决定因素。

UllCORE’s speed and sensitivity will enable clinicians to make better decisions and reduce the risk of over- or under-treatment with antibiotics, in turn supporting the fight against antimicrobial resistance within hospitals. Beyond sepsis, deepull believes its system has the potential to be applicable to a wide range of acute infections..

UllCORE的速度和敏感性将使临床医生能够做出更好的决定，并降低抗生素治疗过度或不足的风险，从而支持医院内对抗菌耐药性的斗争。除了败血症，迪普尔相信其系统有可能适用于广泛的急性感染。。

Today’s unveiling is the result of years of research, enabled by funding from a range of international investors. The product will be debuted at this year’s ESCMID Global 2024 conference, taking place in Barcelona from 27-30 April. Over the coming months deepull is seeking to develop strong partnerships with hospitals and laboratories in anticipation of initiating clinical trials next year.

今天的揭幕是多年研究的结果，由一系列国际投资者提供资金。该产品将于今年4月27日至30日在巴塞罗那举行的ESCMID 2024年全球会议上首次亮相。未来几个月，deepull正寻求与医院和实验室建立强有力的合作伙伴关系，以期明年开始临床试验。

These next steps will be driven forward by the expert deepull team, recently bolstered with the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer..

接下来的这些步骤将由专家deepull团队推动，最近任命金伯利·查宾博士为首席医疗官，韦德·史蒂文森为首席营销和销售官。。

The challenge to identify and treat sepsis is well documented. Sepsis is a contributing factor to 1 in 3 hospital deaths in the US, and septic shock is associated with a mortality rate of 30-40% globally. Early diagnosis is a challenge as the symptoms are non-specific and easy to miss. Current sepsis testing is dominated by complex blood culture tests which can take days to deliver results.

识别和治疗败血症的挑战已得到充分证明。脓毒症是美国三分之一医院死亡的促成因素，感染性休克与全球30-40%的死亡率相关。早期诊断是一项挑战，因为症状非特异性且容易遗漏。目前的败血症检测主要是复杂的血培养检测，可能需要几天才能得出结果。

This method is now over 40 years old and is limited to ‘viable’ organisms, missing a wide range of additional microbial analytes that can be found in blood..

这种方法已有40多年的历史，仅限于“活的”生物体，缺少血液中可以发现的多种其他微生物分析物。。

Jordi Carrera, Chief Executive Officer and Co-Founder of deepull, commented: “Introducing the UllCORE platform and its unique capabilities to the market is a significant milestone for deepull. We are encouraged by early results based on prospectively obtained specimens from septic patients and look forward to initiating clinical trials next year, as well as refining the platform ahead of commercial launch.

deepull首席执行官兼联合创始人乔迪·卡雷拉（Jordi Carrera）评论道：“将UllCORE平台及其独特功能引入市场是deepull的一个重要里程碑。我们对基于脓毒症患者前瞻性采集标本的早期结果感到鼓舞，并期待着明年开始临床试验，并在商业推出之前完善平台。

We believe our UllCORE system could transform the standard of care for sepsis diagnosis, for the benefit of patients globally.”.

我们相信，我们的UllCORE系统可以改变脓毒症诊断的护理标准，造福全球患者。”。

Dr Kimberle Chapin, newly appointed Chief Medical Officer, added: “My experience in the diagnosis of infectious diseases has made it clear to me that more needs to be done to support clinical decision making in the hospital setting. UllCORE has been designed with hospital laboratories in mind, and I look forward to sharing more about its capabilities at ESCMID.”.

新任命的首席医疗官金伯利·查宾博士补充说：“我在传染病诊断方面的经验向我表明，需要做更多的工作来支持医院环境中的临床决策。UllCORE的设计考虑到了医院实验室，我期待着在ESCMID分享更多关于其能力的信息。”。

About deepull

关于deepull

deepull is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx (sold to QIAGEN in 2018), deepull has assembled a team of world-class experts to create rapid and accessible diagnostic solutions.

deepull是一家医疗诊断公司，开发针对败血症和急性感染的无培养诊断解决方案。deepull由STAT Dx（2018年出售给QIAGEN）的创始人于2020年在巴塞罗那成立，成立了一支世界级的专家团队，以创建快速且可访问的诊断解决方案。

deepull is developing a 1 hour, direct-from-blood PCR test targeting 95% of sepsis-causing pathogens. The test will extract total microbial DNA from 8 mL of whole blood and include 50 reportable results. The test runs on the deepull UllCORE instrument; a benchtop system with sample-to-result automation being designed to meet the needs of any hospital clinical laboratory..

deepull正在开发一种针对95%引起败血症的病原体的1小时直接血液PCR检测。该测试将从8毫升全血中提取总微生物DNA，并包括50个可报告的结果。测试在deepull UllCORE仪器上运行；具有样品到结果自动化的台式系统旨在满足任何医院临床实验室的需求。。